Skip to main content
MapleLMS Implementation
Conferences and Meetings 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III

Short name: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
Course start date: 11/08/2025

Sections

General
1 activities

Hematopoietic Stem Cell Transplantation (HCST) Is Underutilized in Black Patients with Myeloid Neoplasms. Results from a Retrospective Study at Chicago's Leading Minority-Serving Hospital
Acute Erythroid Leukemia Clinicopathologic Determinants of Survival: Analysis of a Pooled Database
Association between Targeted Therapy and Survival in Patients with AML
Clinical Implications of Central Nervous System Involvement in Acute Myeloid Leukemia
Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
Epidemiology, Outcomes, and Healthcare Utilization in Acute Myeloid Leukemia: A Study Using the National Inpatient Sample - 2021
High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
Intranasal Corticosteroid Use and Risk of Invasive Fungal Sinusitis in Acute Myeloid Leukemia, Myelodysplastic Syndrome and Post Transplant Patients
Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms
Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy
Predictors of Survival in Core Binding Factor Acute Myeloid Leukemia: An Analysis of the National Cancer Database
Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia
Should “Medically Fit” Older Patients with Acute Myeloid Leukemia (AML) Continue to Receive Intensive Chemotherapy in the Venetoclax (VEN) Era?
Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022